David A. Cory - 11 Mar 2022 Form 4 Insider Report for Eiger BioPharmaceuticals, Inc.

Reporting relationship: President and CEO, Director
Issuer ticker: N/A
Reported as of: 11 Mar 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Mar 2022, 20:06:19 UTC
Prior SEC filing: 30 Jul 2021
Source filing: View source filing
Reporting owner signature: /s/ Sriram Ryali, Attorney-in-Fact

Key filing fact

David A. Cory filed Form 4 for Eiger BioPharmaceuticals, Inc. on 11 Mar 2022.

Key facts

This page summarizes David A. Cory's Form 4 filing for Eiger BioPharmaceuticals, Inc..
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 11 Mar 2022, 20:06.

Change

Previous filing in this sequence was filed on 30 Jul 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EIGR transaction

Common Stock

Award

Transaction value: $0
Shares: +47,000
Change %: +38%
Price: $0.000000
Shares after: 169,183
Date: 11 Mar 2022
Ownership: Direct
Footnotes: F1, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EIGR transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +281,000
Change %
Price: $0.000000
Shares after: 281,000
Date: 11 Mar 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 281,000
Exercise price: $5.10
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents shares underlying Restricted Stock Units award that will vest as to 33.3% on each of the first, second and third anniversaries of the grant date of March 11, 2022.

Footnote F2

The option vests in 48 equal monthly installments commencing on the grant date of March 11, 2022, subject to the Reporting Person's continuous service as of such date.

Footnote F3

Includes shares purchased under the Issuer's Employee Stock Purchase Plans as follows: 1,378 shares on September 5, 2020, 1,459 shares on September 3, 2021, and 1,500 shares on March 5, 2022.